Flubendazole

Flubendazole

SCHEMBL6232065

COC(=O)Nc1nc2ccc(C(=O)c3ccc(F)cc3)cc2[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 3/20 1.00
MAPK1 P28482 2/20 1.00
ADORA3 P0DMS8 1/20 1.00
PTGS1 P23219 1/20 1.00
RXFP1 Q9HBX9 1/20 1.00
LMNA P02545 3/20 0.80
CYP1A2 P05177 3/20 0.80
HIF1A Q16665 3/20 0.80
ALDH1A1 P00352 2/20 0.80
ABL1 P00519 2/20 0.80
CYP2C9 P11712 2/20 0.80
HTT P42858 2/20 0.80
ABCC4 O15439 1/20 0.80
USP2 O75604 1/20 0.80
TUBB4A P04350 3/20 0.65
TUBB P07437 3/20 0.65
TUBA3C P0DPH7 3/20 0.65
TUBA1B P68363 3/20 0.65
TUBA4A P68366 3/20 0.65
TUBB4B P68371 3/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Flubendazole SCHEMBL31704404 1.00 KDR (1.00) KDRMAPK1ADORA3PTGS1RXFP1
Flubendazole SCHEMBL28086273 0.91 KDR (0.82) KDRMAPK1ADORA3PTGS1RXFP1
Flubendazole SCHEMBL167185 0.90 KDR (0.82) KDRMAPK1ADORA3PTGS1RXFP1
Flubendazole SCHEMBL29409278 0.90 KDR (0.82) KDRMAPK1ADORA3PTGS1RXFP1
Flubendazole SCHEMBL22321861 0.89 KDR (0.80) KDRMAPK1ADORA3PTGS1RXFP1
Mebendazole SCHEMBL536464 0.89 ABL1 (1.00) KDRMAPK1ADORA3PTGS1RXFP1
Mebendazole SCHEMBL29390263 0.89 ABL1 (1.00) KDRMAPK1ADORA3PTGS1RXFP1
SCHEMBL24209473 0.89 KDR (0.79) KDRMAPK1ADORA3PTGS1RXFP1
Flubendazole SCHEMBL28142848 0.88 LMNA (0.77) KDRMAPK1ADORA3PTGS1RXFP1
SCHEMBL14375449 0.88 KDR (0.80) KDRMAPK1ADORA3PTGS1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3972591-B1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLUBENDAZOLE ZEPHAPHARM LTD (GB) 2022-12-28 EP claimed
CN-115697058-B Agrochemical adjuvants 禾大国际股份公开有限公司 2025-05-13 CN disclosed
EP-4389116-A1 PHARMACEUTICAL AQUEOUS FLUBENDAZOLE SUSPENSION Dechra Ltd (GB) 2024-06-26 EP disclosed
CN-117825570-A Method for simultaneously detecting imidazole drugs and metabolic residues thereof in food 重庆市计量质量检测研究院 2024-04-05 CN disclosed
US-11935803-B2 Resin composition, laminate, semiconductor wafer with resin composition layer, substrate for mounting semiconductor with resin composition layer and semiconductor device MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2024-03-19 US disclosed
CN-117616018-A Herbicidal aryl dihydrofuran carboxylic acid esters 巴斯夫欧洲公司 2024-02-27 CN disclosed
US-20240050444-A1 TREATMENT METHODS VASCULAR THERAPEUTICS PTY LTD (AU) 2024-02-15 US disclosed
US-20240050943-A1 MULTI-VOLUME MICROCHAMBER-BASED MICROFLUIDIC PLATFORM AND USE THEREOF CORNELL UNIVERSITY 2024-02-15 US disclosed
US-20240050950-A1 GRADIENT-BASED MICROFLUIDIC CIRCUIT, DEVICE, AND METHOD FOR PERFORMING AN ASSAY CORNELL UNIVERSITY 2024-02-15 US disclosed
CN-117561242-A 4-methylsulfonyl benzamide compound, preparation method, weeding composition and application 江苏中旗科技股份有限公司 2024-02-13 CN disclosed
EP-2846788-A1 USE OF COMPOUNDS FOR THE TREATMENT OF PAIN Akron Molecules AG (AT) 2015-03-18 EP disclosed
WO-2013167743-A1 USE OF COMPOUNDS FOR THE TREATMENT OF PAIN AKRON MOLECULES GMBH (AT) 2013-11-14 WO disclosed
US-20130137099-A1 TRANSGENIC REPORTER SYSTEM THAT REVEALS EXPRESSION PROFILES AND REGULATION MECHANISMS OF ALTERNATIVE SPLICING IN MAMMALIAN ORGANISMS KYOTO UNIVERSITY (JP) 2013-05-30 US disclosed
US-20120202840-A1 Use of Flubendazole and Vinca Alkaloids for Treatment of Hematological Diseases UNIVERSITY HEALTH NETWORK (CA) 2012-08-09 US disclosed
US-20120202840-A1 Use of Flubendazole and Vinca Alkaloids for Treatment of Hematological Diseases UNIVERSITY HEALTH NETWORK (CA) 2012-08-09 US disclosed
WO-2011041914-A1 USE OF FLUBENDAZOLE AND VINCA ALKALOIDS FOR TREATMENT OF HEMATOLOGICAL DISEASES UNIVERSITY HEALTH NETWORK (UHN) (CA) 2011-04-14 WO disclosed
EP-0896517-B1 METHOD FOR PROMOTING HAIR, NAIL, AND SKIN KERATINIZATION SCHICK MARY P (US) 2005-05-25 EP disclosed
US-5861142-A DERMATOLOGY AND GROWTH OF HAIR NAILS AND SKIN SCHICK MARY PICHLER (US) 1999-01-19 US disclosed
EP-0090368-B1 ANTHELMINTIC PREPARATIONS HOECHST UK LIMITED (GB) 1987-09-02 EP disclosed
EP-0224249-A1 Amorphous benzimidazole derivatives SYNTEX (U.S.A.) INC. (US) 1987-06-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240050444-A1 TREATMENT METHODS FOSB, FOS, VCAM1 KDR 6/4885MAPK1 91/4885ADORA3 4166/4885
US-20120202840-A1 Use of Flubendazole and Vinca Alkaloids for Treatment of Hematological Diseases MCL1, BCL9, KIT KDR 2342/4885MAPK1 3216/4885ADORA3 56/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.